Madan Jagasia Archives
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Nov. 2, 2018—Vanderbilt-Ingram Cancer Stem Cell Transplant ranks among the best in the nation for donor stem cell transplant survival rates among large centers, according to an annual report.
Jun. 12, 2018—After successfully leading Vanderbilt-Ingram Cancer Center (VICC) through years of growth in patient volumes and enhanced care options, Michael Neuss, MD, Chief Medical Officer of the VICC Clinical Enterprise, is retiring as CMO. Neuss will be succeeded by Madan Jagasia, MBBS, MSCI, MMHC, who has been named to the George and Beverly Rawlings Directorship and is section chief, Hematology and Stem Cell Transplant and director of the Outpatient Stem Cell Clinic.
Oct. 25, 2017—Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.
Mar. 3, 2016—For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system.
Dec. 11, 2014—When Darlena Clark of Hendersonville, Tennessee, saw Jon Strong for the first time at Nashville International Airport she, “just grabbed him and hugged him and just held on.”